IRIDEX Corporation, an ophthalmic medical technology company, provides therapeutic based laser systems, delivery devices, and consumable instrumentation to treat sight-threatening eye diseases in ophthalmology.
Price History & Performance
|Historical stock prices|
|Current Share Price||US$7.55|
|52 Week High||US$1.60|
|52 Week Low||US$9.71|
|1 Month Change||4.57%|
|3 Month Change||14.57%|
|1 Year Change||287.40%|
|3 Year Change||35.55%|
|5 Year Change||-43.11%|
|Change since IPO||-26.34%|
Recent News & Updates
|IRIX||US Medical Equipment||US Market|
Return vs Industry: IRIX exceeded the US Medical Equipment industry which returned 23.1% over the past year.
Return vs Market: IRIX exceeded the US Market which returned 30.3% over the past year.
Stable Share Price: IRIX is not significantly more volatile than the rest of US stocks over the past 3 months, typically moving +/- 8% a week.
Volatility Over Time: IRIX's weekly volatility has decreased from 14% to 8% over the past year.
About the Company
IRIDEX Corporation, an ophthalmic medical technology company, provides therapeutic based laser systems, delivery devices, and consumable instrumentation to treat sight-threatening eye diseases in ophthalmology. It offers laser consoles, such as Cyclo G6 laser system for use in the treatment of glaucoma; IQ 532 and IQ 577 laser photocoagulation systems, which are used for the treatment of diabetic macular edema and other retinal diseases; and OcuLight TX, OcuLight SL, OcuLight SLx, OcuLight GL, and OcuLight GLx laser photocoagulation systems that are used to treat proliferative diabetic retinopathy, macular holes, retinal tears, and detachments. The company also provides delivery devices, including TxCell scanning laser delivery system that allows the physician to perform multi-spot pattern scanning; slit lamp adapter, which allows the physician to utilize a standard slit lamp in diagnosis and treatment procedures; and laser indirect ophthalmoscope for use in procedures to treat peripheral retinal disorders.
IRIDEX Fundamentals Summary
|IRIX fundamental statistics|
Is IRIX overvalued?See Fair Value and valuation analysis
Earnings & Revenue
|IRIX income statement (TTM)|
|Cost of Revenue||US$26.21m|
Last Reported Earnings
Jul 03, 2021
Next Earnings Date
|Earnings per share (EPS)||-0.16|
|Net Profit Margin||-5.41%|
How did IRIX perform over the long term?See historical performance and comparison
Is IRIDEX undervalued compared to its fair value and its price relative to the market?
Undervalued compared to fair value
Share Price vs. Fair Value
Below Fair Value: IRIX ($7.55) is trading below our estimate of fair value ($128.1)
Significantly Below Fair Value: IRIX is trading below fair value by more than 20%.
Price To Earnings Ratio
PE vs Industry: IRIX is unprofitable, so we can't compare its PE Ratio to the US Medical Equipment industry average.
PE vs Market: IRIX is unprofitable, so we can't compare its PE Ratio to the US market.
Price to Earnings Growth Ratio
PEG Ratio: Insufficient data to calculate IRIX's PEG Ratio to determine if it is good value.
Price to Book Ratio
PB vs Industry: IRIX is overvalued based on its PB Ratio (4.4x) compared to the US Medical Equipment industry average (4.3x).
How is IRIDEX forecast to perform in the next 1 to 3 years based on estimates from 2 analysts?
Forecasted annual earnings growth
Earnings and Revenue Growth Forecasts
Analyst Future Growth Forecasts
Earnings vs Savings Rate: IRIX is forecast to remain unprofitable over the next 3 years.
Earnings vs Market: IRIX is forecast to remain unprofitable over the next 3 years.
High Growth Earnings: IRIX is forecast to remain unprofitable over the next 3 years.
Revenue vs Market: IRIX's revenue (15.5% per year) is forecast to grow faster than the US market (9.9% per year).
High Growth Revenue: IRIX's revenue (15.5% per year) is forecast to grow slower than 20% per year.
Earnings per Share Growth Forecasts
Future Return on Equity
Future ROE: Insufficient data to determine if IRIX's Return on Equity is forecast to be high in 3 years time
How has IRIDEX performed over the past 5 years?
Historical annual earnings growth
Earnings and Revenue History
Quality Earnings: IRIX is currently unprofitable.
Growing Profit Margin: IRIX is currently unprofitable.
Past Earnings Growth Analysis
Earnings Trend: IRIX is unprofitable, but has reduced losses over the past 5 years at a rate of 7.4% per year.
Accelerating Growth: Unable to compare IRIX's earnings growth over the past year to its 5-year average as it is currently unprofitable
Earnings vs Industry: IRIX is unprofitable, making it difficult to compare its past year earnings growth to the Medical Equipment industry (36.1%).
Return on Equity
High ROE: IRIX has a negative Return on Equity (-9.36%), as it is currently unprofitable.
How is IRIDEX's financial position?
Financial Position Analysis
Short Term Liabilities: IRIX's short term assets ($43.7M) exceed its short term liabilities ($10.9M).
Long Term Liabilities: IRIX's short term assets ($43.7M) exceed its long term liabilities ($12.7M).
Debt to Equity History and Analysis
Debt Level: IRIX is debt free.
Reducing Debt: IRIX had no debt 5 years ago.
Cash Runway Analysis
For companies that have on average been loss making in the past we assess whether they have at least 1 year of cash runway.
Stable Cash Runway: Whilst unprofitable IRIX has sufficient cash runway for more than 3 years if it maintains its current positive free cash flow level.
Forecast Cash Runway: IRIX is unprofitable but has sufficient cash runway for more than 3 years, even with free cash flow being positive and shrinking by 2.8% per year.
What is IRIDEX current dividend yield, its reliability and sustainability?
Dividend Yield vs Market
Notable Dividend: Unable to evaluate IRIX's dividend yield against the bottom 25% of dividend payers, as the company has not reported any recent payouts.
High Dividend: Unable to evaluate IRIX's dividend yield against the top 25% of dividend payers, as the company has not reported any recent payouts.
Stability and Growth of Payments
Stable Dividend: Insufficient data to determine if IRIX's dividends per share have been stable in the past.
Growing Dividend: Insufficient data to determine if IRIX's dividend payments have been increasing.
Current Payout to Shareholders
Dividend Coverage: Insufficient data to calculate payout ratio to determine if its dividend payments are covered by earnings.
Future Payout to Shareholders
Future Dividend Coverage: No need to calculate the sustainability of IRIX's dividend in 3 years as they are not forecast to pay a notable one for the US market.
How experienced are the management team and are they aligned to shareholders interests?
Average management tenure
David Bruce (62 yo)
Mr. David I. Bruce has been President and Chief Executive Officer at IRIDEX Corporation since May 21, 2019. Mr. Bruce has been a Director of IRIDEX Corporation since April 13, 2018. He served as the Chief...
CEO Compensation Analysis
Compensation vs Market: David's total compensation ($USD650.92K) is about average for companies of similar size in the US market ($USD542.68K).
Compensation vs Earnings: David's compensation has been consistent with company performance over the past year.
Experienced Management: IRIX's management team is considered experienced (2.4 years average tenure).
Experienced Board: IRIX's board of directors are not considered experienced ( 2.5 years average tenure), which suggests a new board.
Who are the major shareholders and have insiders been buying or selling?
Insider Trading Volume
Insider Buying: Insufficient data to determine if insiders have bought more shares than they have sold in the past 3 months.
Recent Insider Transactions
Dilution of Shares: Shareholders have been diluted in the past year, with total shares outstanding growing by 14%.
IRIDEX Corporation's employee growth, exchange listings and data sources
- Name: IRIDEX Corporation
- Ticker: IRIX
- Exchange: NasdaqGM
- Founded: 1989
- Industry: Health Care Equipment
- Sector: Healthcare
- Market Cap: US$119.534m
- Shares outstanding: 15.83m
- Website: https://www.iridex.com
Number of Employees
- IRIDEX Corporation
- 1212 Terra Bella Avenue
- Mountain View
- United States
Company Analysis and Financial Data Status
|Data||Last Updated (UTC time)|
|Company Analysis||2021/10/23 22:20|
|End of Day Share Price||2021/10/22 00:00|
Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here.